Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Precigen Stock Quote

Precigen (NASDAQ: PGEN)

$1.29
(-2.2%)
-$0.03
Price as of April 19, 2024, 3:22 p.m. ET

Precigen Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
PGEN +13.79% -67.88% -20.30% -95%
S&P +20.62% +72.50% +11.51% +195%

Precigen Company Info

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

News & Analysis

The Fool has written over 100 articles on Precigen.

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.